NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
Includes Data from More than Twenty-Five Studies, Including Six Using GeoMx Digital Spatial Profiler
SEATTLE, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ platforms that will be presented at the 33nd Annual Meeting of the Society of Immunotherapy for Cancer (SITC).
“We are thrilled to see a number of high-profile abstracts that include data from our GeoMx Digital Spatial Profiler at the 2018 SITC conference,” said Brad Gray, president and chief executive officer of NanoString. “The ability to quantify high-plex protein and RNA simultaneously can be a powerful tool for identifying and validating biomarkers, especially for applications in immuno-oncology.”
More than 25 abstracts using NanoString’s nCounter platform will be presented at the SITC Annual Meeting, being held at the Walter E. Washington Convention Center in Washington, D.C., Nov. 7-11, 2018. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.
Six studies included the use of NanoString’s GeoMx Digital Spatial Profiler (DSP) platform in immuno-oncology research. These abstracts include numbers 031, P113, P131, P389, P428 and P429 that are included in the table below. DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format. DSP is expected to be commercially available with the launch of a new instrument planned for mid-2019, and is currently accessible through the company’s Technology Access Program (TAP). NanoString is currently accepting applications for the TAP for its DSP technology at [email protected].
Each year, SITC recognizes publications that demonstrated excellence in scientific research with its Journal for ImmunoTherapy of Cancer (JITC) best paper awards. The 2018 JITC “Best Basic Science Paper” was awarded for “Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA),” to a team led by NanoString researchers that included, Patrick Danaher, Ph.D., Sarah Warren, Ph.D., Rongze Lu, Ph.D., Josue Samayoa, Ph.D., Amy Sullivan, B.S., Irena Pekker, Ph.D., Brett Wallden, M.S., Francesco M. Marincola, M.D., and Alessandra Cesano, M.D., Ph.D.
NanoString will host a Key Opinion Leader Dinner for Digital Spatial Profiling on the evening of Thursday, Nov. 8th. The dinner features presentations by leading academic and biopharma researchers on the use of nCounter gene expression and GeoMx Digital Spatial Profiling technologies to discover biomarkers for treating bladder cancer and melanoma.
At the 2018 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and Digital Spatial Profiling at booth #600.
| Abstract # | Title | Presenting Author |
| O31 | Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma | David Page, MDProvidence Portland Cancer Center, Portland, OR,USA |
| O45 | Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444 | Lawrence Fong, MDUniversity of California, San Francisco, CA, USA |
| P25 | Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types | Albert Candia, PhDDynavax Technologies, Berkeley, CA, USA |
| P35 | Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928 | Daniel DiRenzo, PhDArcus Biosciences, Hayward, CA, USA |
| P43 | The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors | Colt Egelston, PhDBeckman Research Institute, City of Hope, Duarte,CA, USA |
| P53 | X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma | Robert Andtbacka, MDHuntsman Cancer Institute, Salt Lake City, UT, USA |
| P54 | Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444 | Andrew Hotson, PhDCorvus Pharmaceuticals, Burlingame, CA, USA |
| P67 | Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer | Melba Marie Page, PhDNilogen Oncosystems, Tampa, FL, USA |
| P87 | Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial | Luc R. Desnoyers, PhDCytomX Therapeutics, Inc., South San Francisco, CA,USA |
| P113 | Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia | Sergio Rutella, MD, PhDNottingham Trent University, Nottingham, UK |
| P131 | High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling | David Rimm, MD, PhDYale University School of Medicine, New Haven, CT,USA |
| P136 | Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab | Breelyn Wilky, MD University of Miami - SCCC, Miami, FL, USA |
| P139 | "Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell | Funda Meric-Bernstam, MDMD Anderson Cancer Center, Houston, USA |
| P327 | Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma | Ahmad Halwani, MDHuntsman Cancer Institute, Salt Lake City, UT, USA |
| P349 | Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model | Phyllis Cheung, PhDUniversity Hospital Essen, DKFZ, Essen, Germany |
| P354 | Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer | Pierre-Olivier GaudreauMD Anderson Cancer Center, Houston, USA |
| P360 | Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody | Qun Jiang, PhDNational Institutes of Health, Bethesda, MD, USA |
| P389 | Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab | Trieu My Van, PhDNKI/Nanostring, Amsterdam, Netherlands |
| P428 | Spatially-resolved, high-plex digital profiling enables characterization of complex immune biology of the colorectal cancer microenvironment | Sarah Church, PhDNanoString Technologies, Seattle, WA, USA |
| P429 | Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma | Carmen Ballesteros Merino, PhD, Providence Portland Cancer Center, Portland, OR,USA |
| P450 | The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models | Luis Carvajal, PhDAileron Therapeutics, Inc., Cambridge, MA, USA |
| P460 | Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer | Sarah Nersesian, MScQueen's University, Kingston, ON, Canada |
| P468 | Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod | Mariya Rozenblit, MDYale University, Connecticut, CT, USA |
| P564 | Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis | Daniel Johnson, MDMD Anderson Cancer Center, Houston, TX, USA |
| P597 | Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA | Nicola Annels, PhDThe University of Surrey, Guildford, UK |
| P614 | Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses | Amanda McDaniel, BAPulse Biosciences, Burlingame, CA, USA |
| P650 | Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function | Vanessa Buatois, PhDNovimmune SA, Geneva, Switzerland |
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
NanoString, NanoString Technologies, the NanoString logo, GeoMx DSP, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug FarrellVice President, Investor Relations & Corporate Communications[email protected]Phone: 206-602-1768
